Enwei Pharmaceutical Co., Ltd. (SHE:301331)

China flag China · Delayed Price · Currency is CNY
19.35
-0.81 (-4.02%)
At close: Jul 30, 2026
Market Cap1.97B -47.0%
Revenue (ttm)879.60M +6.6%
Net Income48.14M +6.1%
EPS0.46 +2.7%
Shares Out 101.88M
PE Ratio41.74
Forward PEn/a
Dividend0.66 (3.27%)
Ex-Dividend DateMay 28, 2026
Volume3,128,417
Open19.87
Previous Close20.16
Day's Range19.11 - 20.15
52-Week Range18.87 - 39.66
Beta0.55
Analystsn/a
Price Targetn/a
Earnings DateAug 27, 2026

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines and chemical drugs in China. The company offers drugs in the areas of gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology under the Jieeryin, Haowayou, and Likeshu brands. It also provides products for cold and fever relief, dental care, warming/nourishing/tonic purposes, and other uses; ointments, suppositories, capsules, effervescent tablets, and... [Read more]

Sector Healthcare
Founded 1986
Employees 1,501
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301331
Full Company Profile

Financial Performance

In 2025, Enwei Pharmaceutical's revenue was 900.77 million, an increase of 10.91% compared to the previous year's 812.13 million. Earnings were 51.94 million, an increase of 38.53%.

Financial Statements